Substantia Nigra Hyperechogenicity

Toomsoo, Toomas; Liepelt‐Scarfone, Inga; Kerner, Riina; Kadastik-Eerme, Liis; Asser, Toomas; Rubanovits, Inna; Berg, Daniela; Taba, Pille

doi:10.7863/ultra.14.12069

Cited by 9 publications

(3 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TCS can be used to demonstrate the characteristic structural changes of the SN in PD patients by using the principle of ultrasound imaging. The sensitivity of TCS in the diagnosis of PD is between 91 and 100% ( 50 , 51 ). In 2013, the European Federation of Neurological Societies and the Movement Disorders Society recommended the finding of SN echogenic intensity > grade II and hyperechoic area > 0.25 cm 2 on TCS as level A evidence for differentiating primary PD from atypical Parkinson’s syndrome, for early diagnosis of PD, and for screening patients at high risk for PD ( 52 ).…”

Section: Discussion and Summarymentioning

confidence: 99%

“…Recent research in the field of PD has increasingly focused on the varied manifestations of the disease, particularly the distinctions between the postural instability gait difficulty (PIGD) and tremor dominant (TD) subtypes ( 50 , 51 ). Transcranial sonography (TCS), which detects hyperechogenicity of the substantia nigra (HSN), presents a valuable tool in exploring these differences.…”

Section: The Association Between Sn Hyperechogenicity and Pd Subtypesmentioning

confidence: 99%

See 1 more Smart Citation

Advancements in understanding substantia nigra hyperechogenicity via transcranial sonography in Parkinson’s disease and its clinical implications

Zhang,

Jiang,

Zhu

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

Amidst rising Parkinson’s disease (PD) incidence in an aging global population, the need for non-invasive and reliable diagnostic methods is increasingly critical. This review evaluates the strategic role of transcranial sonography (TCS) in the early detection and monitoring of PD. TCS’s ability to detect substantia nigra hyperechogenicity offers profound insights into its correlation with essential neuropathological alterations—namely, iron accumulation, neuromelanin depletion, and glial proliferation—fundamental to PD’s pathophysiology. Our analysis highlights TCS’s advantages, including its non-invasiveness, cost-effectiveness, and ease of use, positioning it as an invaluable tool for early diagnosis and continual disease progression monitoring. Moreover, TCS assists in identifying potential risk and protective factors, facilitating tailored therapeutic strategies to enhance clinical outcomes. This review advocates expanding TCS utilization and further research to maximize its diagnostic and prognostic potential in PD management, contributing to a more nuanced understanding of the disease.

show abstract

Section: Discussion and Summarymentioning

confidence: 99%

Section: The Association Between Sn Hyperechogenicity and Pd Subtypesmentioning

confidence: 99%

Advancements in understanding substantia nigra hyperechogenicity via transcranial sonography in Parkinson’s disease and its clinical implications

Zhang,

Jiang,

Zhu

et al. 2024

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…However, the SNH can also be detected in 9% of clinically healthy people (from 8% to 15%) [26,28,29]. According to studies the sensitivity and specificity of the method in differentiating individuals with PD from control patients is 80-93%, and 76-92%, respectively [29][30][31][32]. It is believed that the area of SN does not change and remains stable throughout the disease, despite the clinical deterioration and progression of the process from the initial stages to severe disability [33,34].…”

Section: Instrumental Testsmentioning

confidence: 99%

Parkinson’s Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization

et al. 2020

View full text Add to dashboard Cite

Parkinson’s disease is the second most frequent neurodegenerative disease, representing a significant medical and socio-economic problem. Modern medicine still has no answer to the question of why Parkinson’s disease develops and whether it is possible to develop an effective system of prevention. Therefore, active work is currently underway to find ways to assess the risks of the disease, as well as a means to extend the life of patients and improve its quality. Modern studies aim to create a method of assessing the risk of occurrence of Parkinson’s disease (PD), to search for the specific ways of correction of biochemical disorders occurring in the prodromal stage of Parkinson’s disease, and to personalize approaches to antiparkinsonian pharmacotherapy. In this review, we summarized all available clinically approved tests and techniques for PD diagnostics. Then, we reviewed major improvements and recent advancements in genomics, transcriptomics, and proteomics studies and application of metabolomics in PD research, and discussed the major metabolomics findings for diagnostics and therapy of the disease.

show abstract

Ecografía transcraneal mesencefálica en el estudio de enfermedad de Parkinson y su diagnóstico diferencial con parkinsonismos en un hospital público de Tucumán

Castro

Noble

2017

Neurología Argentina

View full text Add to dashboard Cite

Substantia Nigra Hyperechogenicity

Abstract: This study indicates the diagnostic merit of transcranial sonography in PD diagnosis in an additional population and demonstrates that transcranial sonography of the substantia nigra is a relevant and useful diagnostic tool for patients with PD.

Cited by 9 publications

References 34 publications

Advancements in understanding substantia nigra hyperechogenicity via transcranial sonography in Parkinson’s disease and its clinical implications

Advancements in understanding substantia nigra hyperechogenicity via transcranial sonography in Parkinson’s disease and its clinical implications

Parkinson’s Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization

Ecografía transcraneal mesencefálica en el estudio de enfermedad de Parkinson y su diagnóstico diferencial con parkinsonismos en un hospital público de Tucumán

Contact Info

Product

Resources

About